1Department of Internal Medicine, Hanyang University, Korea
2Department of Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
3Department of Pulmonary Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
4Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Copyright © 2016 The Korean Society of Critical Care Medicine
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Patient no. | Sex/Age | Malignancy | Therapy and disease status (days since therapy) | APACHE II | LIS | RESP Score (group) | ECMO duration hours (days) | Type of ECMO | ECMO weaning | Bleeding | Cause of death |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | M/54 | CML | HSCT (294), CR | 29 | 3.5 | 0 (III) | 245 (11) | VV | No | Major | DAH |
2 | M/26 | Precursor T-cell lymphoma | HSCT (260), Relapsed | 17 | 3.3 | -4 (IV) | 266 (12) | VA | No | Major | ICH |
3 | F/16 | AA | HSCT (1) | 29 | 3.8 | 0 (III) | 108 (5) | VV | Yes | Minor | Sepsis |
4 | F/56 | MM | HSCT (34) | 41 | 3.5 | -4 (IV) | 394 (17) | VA | No | Minor | Sepsis |
5 | M/28 | CML | HSCT (221), CR, graft failure | 26 | 3.3 | 4 (II) | 92 (4) | VA | Yes | - | Sepsis |
6 | F/43 | MDS | HSCT (20) | 25 | 3.8 | -2 (IV) | 18 (1) | VA | No | - | MOF |
7 | F/33 | HLH | HSCT (20) | 19 | 3.5 | -13 (V) | 4 (1) | VV | No | - | Pneumonia |
8 | F/51 | AML | Consolidation (19), CR | 31 | 3.5 | 0 (III) | 4 (1) | VA | No | - | Sepsis |
9 | M/41 | AML | HSCT (14), CR | 29 | 3.0 | -6 (V) | 7 (1) | VA | No | - | Pneumonia |
10 | F/45 | BAL | HSCT (1519), CR | 40 | 2.5 | -8 (V) | 452 (19) | VV | No | - | Sepsis |
11 | M/51 | Diffuse large B-cell lymphoma | Induction on ECMO | 29 | 3.3 | -2 (IV) | 176 (8) | VV | No | - | MOF |
12 | M/62 | AML | HSCT (0), CR | 39 | 3.0 | -2 (IV) | 4 (1) | VV | No | - | Pneumonia |
13 | M/58 | Transformation of MDS to AML | - | 39 | 2.3 | 0 (III) | 36 (2) | VV | No | - | Sepsis |
14 | M/54 | AML | Induction (61), CR | 14 | 3.5 | -4 (IV) | 42 (2) | VA | Yes | - | MOF |
15 | M/31 | MDS | Azacitidine, Danazol | 31 | 2.8 | -2 (IV) | 36 (2) | VA | No | - | Sepsis |
Characteristic | Value |
---|---|
Arterial blood gas analysis | |
pH | 7.22 (7.14–7.29) |
PaCO2 (mmHg) | 52.0 (44.0–68.4) |
PaO2 (mmHg) | 45.0 (36.0–57.0) |
PaO2/FiO2 ratio | 47.0 (36.0–57.0) |
Lactate (mmol/L) | 4.7 (1.0–7.0) |
Complete blood cell count | |
Leukocyte (×103/μL) | 1.1 (0.1–8.2) |
Hemoglobin (g/dL) | 10.7 (8.4–11.7) |
Platelet (×103/μL) | 51.0 (23.0–64.0) |
Vasopressor, n (%) | 15 (100) |
Hemofiltration, n (%) | 8 (53) |
APACHE II score: The Acute Physiology and Chronic Health Evaluation II score; LIS: lung injury score; RESP score: respiratory extracorporeal membrane oxygenation survival prediction score; ECMO: extracorporeal membrane oxygenation; CML: chronic myeloid leukemia; HSCT: hematopoietic stem cell transplantation; CR: complete remission; VV: venovenous; DAH: diffuse alveolar hemorrhage; VA: venoarterial; ICH: intracranial hemorrhage; AA: aplastic anemia; MM: multiple myeloma; MDS: myeloid dysplasia syndrome; MOF: multiple organ failure; HLH: hemophagocytic lymphohistiocytosis; AML: acute myeloid leukemia; BAL: biphenotypic acute leukemia.
The data are presented as the median and interquartile range (25–75%) for continuous variables or number and percentage for non-continuous variables. ECMO: extracorporeal membrane oxygenation.